NeuroPace (NASDAQ:NPCE) Research Coverage Started at UBS Group

UBS Group started coverage on shares of NeuroPace (NASDAQ:NPCEFree Report) in a research report report published on Tuesday, Marketbeat.com reports. The firm issued a buy rating and a $17.00 price objective on the stock.

A number of other equities research analysts also recently weighed in on NPCE. JPMorgan Chase & Co. boosted their price target on shares of NeuroPace from $9.00 to $14.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 17th. Wells Fargo & Company cut their price target on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $15.33.

Read Our Latest Analysis on NeuroPace

NeuroPace Stock Performance

NASDAQ NPCE opened at $14.02 on Tuesday. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.15. The company has a 50 day moving average of $11.22 and a 200-day moving average of $8.56. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03. The firm has a market cap of $418.47 million, a price-to-earnings ratio of -14.02 and a beta of 2.02.

NeuroPace (NASDAQ:NPCEGet Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.26) by $0.07. The business had revenue of $21.06 million for the quarter, compared to analysts’ expectations of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same period in the prior year, the firm earned ($0.28) earnings per share. On average, equities analysts forecast that NeuroPace will post -1 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NeuroPace

Several institutional investors have recently added to or reduced their stakes in NPCE. JPMorgan Chase & Co. boosted its position in shares of NeuroPace by 106.3% during the third quarter. JPMorgan Chase & Co. now owns 11,997 shares of the company’s stock worth $84,000 after buying an additional 6,181 shares during the period. Rhumbline Advisers bought a new position in shares of NeuroPace during the 2nd quarter worth approximately $111,000. Financial Advocates Investment Management raised its holdings in shares of NeuroPace by 20.0% in the third quarter. Financial Advocates Investment Management now owns 18,000 shares of the company’s stock valued at $125,000 after purchasing an additional 3,000 shares during the last quarter. Barclays PLC raised its holdings in shares of NeuroPace by 346.0% in the third quarter. Barclays PLC now owns 20,633 shares of the company’s stock valued at $144,000 after purchasing an additional 16,007 shares during the last quarter. Finally, XTX Topco Ltd lifted its position in shares of NeuroPace by 56.1% in the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock worth $182,000 after purchasing an additional 8,643 shares in the last quarter. 78.83% of the stock is owned by institutional investors.

NeuroPace Company Profile

(Get Free Report)

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.

Further Reading

Analyst Recommendations for NeuroPace (NASDAQ:NPCE)

Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.